TICKERNERD
Menu
PBLSHealthcare · Biotechnology

PBLS Stock Forecast: Parabilis Medicines, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$30
−0.53% on the day

The 5 Wall Street analysts covering Parabilis Medicines, Inc. hold a median 12-month price target of $41 — +35.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 3 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.7B
Ticker Nerd rank
0 / 100
Median analyst target
$41
Analysts covering
5
Revenue$148K
Operating income−$50.9M
Net income−$52.5M
Free cash flow−$4.2M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.9%
1M
−24.5%
From high
−27.4%
From low
+51.4%
$20
$42
Range since 8 June 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

PBLS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Parabilis Medicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
0 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
29
Size
27
Value
15
Momentum
12
Accruals
8
Growth
8
Issuance
7
Quality
4
Volatility
4

Revisions (29): Analysts have, on balance, been raising their forecasts.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PBLS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PBLS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 8 June 2026Adjusted close, US dollars
$20$25$30$35$40$45Jul 26Aug 26Sep 26Oct 26PBLSHigh $45Median $41Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $40Median $41High $45

The green dot is the last close — the median target sits +35.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 July 2026B of A SecuritiesInitiatesBuy—
6 July 2026B of A SecuritiesInitiatesBuy$45
6 July 2026GuggenheimInitiatesBuy—
6 July 2026GuggenheimInitiatesBuy$40
6 July 2026Leerink PartnersInitiatesOutperform—
6 July 2026Leerink PartnersInitiatesOutperform$40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PBLS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PBLS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

PBLS vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200220Jul 26Aug 26Sep 26Oct 26PBLSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PBLS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Parabilis Medicines, Inc. (PBLS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−16.8×

Cheaper than 95% of US stocks

Price / sales
25274.2×

Cheaper than 1% of US stocks

Price / book
3.6×

Cheaper than 28% of US stocks

EV / EBITDA
−15.8×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−34382.4%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
1131.3%

Higher than 99% of US stocks

Return on assets
−231.3%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Parabilis Medicines, Inc. (PBLS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Parabilis Medicines, Inc. has a market value of $3.7B and an enterprise value of $2.7B.

  • Revenue in the twelve months to 30 June 2026: $148K.

  • Net income over the same four quarters: −$170.9M, a −115483.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.26.

  • Free cash flow in the twelve months to 30 June 2026: −$119.1M.

  • Shares outstanding: 123.5M.

  • Trailing P/E: −16.8×; forward P/E: −13.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Parabilis Medicines, Inc. employs 145 people — $1K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

PBLS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PBLSParabilis Medicines, Inc.$3.7B
0
XENEXenon Pharmaceuticals, Inc.$3.6B
41
CELCCelcuity, Inc.$3.5B
28
IDYAIDEAYA Biosciences, Inc.$3.5B
78
ACADACADIA Pharmaceuticals, Inc.$3.4B
77
TARSTarsus Pharmaceuticals, Inc.$3.4B
82
VKTXViking Therapeutics, Inc.$3.8B
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Parabilis Medicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PBLS news & analysis

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Parabilis Medicines, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and Seeking Alpha published a transcript of the presentation. The transcript captures the company's remarks and discussion during the conference session.

Why it matters — The transcript offers PBLS watchers insight into the company's current positioning and messaging as presented to an investment audience at a major healthcare conference.

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewsWire · 1 Sept 2026neutral

Parabilis Medicines announced that its Chairman, President and Chief Executive Officer Mathai Mammen, M.D. will participate in the Morgan Stanley 24th Annual Global Healthcare Conference. The clinical-stage biopharmaceutical company, which focuses on unlocking historically undruggable targets for serious diseases, made the announcement on September 1, 2026.

Why it matters — A PBLS watcher would care because the CEO's planned participation at a major investor healthcare conference offers the company a platform to present its pipeline and strategy to the investment community.

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.

GlobeNewsWire · 25 Aug 2026positive

Parabilis Medicines announced the appointment of Craig L. Tendler, M.D., an accomplished drug development leader, to its team. The appointment was disclosed in a company announcement on August 25, 2026.

Why it matters — PBLS watchers would care because the addition of an experienced drug development executive could strengthen the company's clinical-stage capabilities as it pursues its pipeline.

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform

Seeking Alpha · 14 Aug 2026positive

The article discusses Parabilis Medicines' use of rare, genetically simple tumors to validate its Helicon platform for broader oncology applications. It notes the company holds $1.1 billion in cash with a runway into 2030, and reports early zolucatetide data in desmoid tumors showing 100% tumor reduction, 74% objective response, and a favorable safety profile versus competitors.

Why it matters — PBLS watchers would care because the early efficacy and safety data in desmoid tumors could serve as validation for the Helicon platform's applicability to broader oncology targets, supported by a long cash runway into 2030.

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 13 Aug 2026positive

Parabilis Medicines reported its second quarter 2026 financial results and provided business updates. The company is advancing zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward a planned Phase 3 registrational trial in desmoid tumors.

Why it matters — A PBLS watcher would care because the update signals pipeline progress for zolucatetide, its lead candidate, moving toward a pivotal Phase 3 trial in desmoid tumors.

FAQ

Frequently asked questions about PBLS stock

What is the PBLS stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Parabilis Medicines, Inc. have a median 12-month price target of $41, with estimates ranging from $40 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PBLS stock a buy right now?

Of the 5 analysts covering Parabilis Medicines, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Parabilis Medicines, Inc. 0 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PBLS?

As at 3 Oct 2026, Parabilis Medicines, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (29 of 100).

Will PBLS stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +35.4% from the last close, and Ticker Nerd's factor model ranks Parabilis Medicines, Inc. 0 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PBLS stock forecast for 2030?

No analyst covering Parabilis Medicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBLS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $45 over the next 12 months.

What does Parabilis Medicines, Inc. do?

Parabilis Medicines, Inc. Common Stock is the equity of Parabilis Medicines, a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for serious diseases.

What is the latest news on PBLS?

The most recent item we track (Seeking Alpha, 16 Sept 2026): "Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Parabilis Medicines, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and Seeking Alpha published a transcript of the presentation. The transcript captures the company's remarks and discussion during the conference session.

Company

About Parabilis Medicines, Inc.

Parabilis Medicines, Inc. Common Stock is the equity of Parabilis Medicines, a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for serious diseases. The company uses its Helicon discovery platform to design stabilized peptides that can interact with proteins often considered difficult to target with conventional medicines. Its current pipeline includes programs aimed at intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical candidate, zolucatetide, designed to inhibit the β-catenin and TCF interaction in the Wnt/β-catenin signaling pathway. Parabilis Medicines serves the healthcare and life sciences sectors, with a particular emphasis on oncology and other diseases driven by complex protein signaling.

CEO Dr. Mathai Mammen M.D., Ph.D. · 145 employees · United States · https://parabilismed.com